PDE5A and androgen insensitivity syndrome: PDE5 inhibitors mainly tadalafil and sildenafil improve clinical outcomes in AIS patients by regulating cerebral perfusion and CBF via regulation of the neuronal cGMP/NO pathway which also improves cognitive function and mitigate neuroinflammation in AIS.